{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:39Z","timestamp":1792787979204,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mahidol University","id":[{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15997-1","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:27:57Z","timestamp":1776688077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival of myelodysplastic syndrome patients after azacitidine therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Kanticha","family":"Thammagul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suppalux","family":"Limpiwattakee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichika","family":"Chantrathammachart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teeraya","family":"Puavilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suporn","family":"Chuncharunee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimjai","family":"Niparuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"3","key":"15997_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/leu.2013.343","volume":"28","author":"R Itzykson","year":"2014","unstructured":"Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia. 2014;28(3):497\u2013506.","journal-title":"Leukemia"},{"issue":"6","key":"15997_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0081-8","volume":"8","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates. Blood Cancer J. 2018;8(6):1\u20134.","journal-title":"Blood Cancer J"},{"key":"15997_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620720955006","volume":"11","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high risk myelodysplastic syndrome. Therapeutic Adv Hematol. 2020;11:1\u201322.","journal-title":"Therapeutic Adv Hematol"},{"issue":"7","key":"15997_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3324\/haematol.2020.248955","volume":"105","author":"E Hellstr\u00f6m-Lindberg","year":"2020","unstructured":"Hellstr\u00f6m-Lindberg E, Tobiasson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105(7):1765\u201379.","journal-title":"Haematologica"},{"issue":"1","key":"15997_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13643-018-0805-7","volume":"7","author":"J Almasri","year":"2018","unstructured":"Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, et al. A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. Syst Rev. 2018;7(1):144.","journal-title":"Syst Rev"},{"issue":"1","key":"15997_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jgo.2013.08.004","volume":"5","author":"HK Al-Ali","year":"2014","unstructured":"Al-Ali HK, Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol. 2014;5(1):89\u2013105.","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"15997_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clml.2021.01.024","volume":"21","author":"W Liu","year":"2021","unstructured":"Liu W, Zhou Z, Chen L, Wang X. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Clin Lymphoma Myeloma Leuk. 2021;21(6):530\u201344.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"15997_CR8","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/s41375-019-0416-x","volume":"33","author":"MY Follo","year":"2019","unstructured":"Follo MY, Pellagatti A, Armstrong RN, Ratti S, Mongiorgi S, De Fanti S, et al. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia. 2019;33(9):2276\u201390.","journal-title":"Leukemia"},{"key":"15997_CR9","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1182\/blood-2019-122122","volume":"143","author":"J Fulcher","year":"2019","unstructured":"Fulcher J, Alshammasi ZA, Cantor N, Bredeson C, Christou G, Maze D, et al. Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome\/Low Blast Count AML. Blood. 2019;143:5156.","journal-title":"Blood"},{"issue":"45","key":"15997_CR10","doi-asserted-by":"publisher","first-page":"27882","DOI":"10.18632\/oncotarget.25328","volume":"9","author":"A Kuendgen","year":"2018","unstructured":"Kuendgen A, M\u00fcller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, et al. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget. 2018;9(45):27882\u201394.","journal-title":"Oncotarget"},{"issue":"3","key":"15997_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00277-020-03932-8","volume":"99","author":"I Mart\u00edn","year":"2020","unstructured":"Mart\u00edn I, Navarro B, Serrano A, Villam\u00f3n E, Calabuig M, Solano C, et al. Impact of Clinical Features, Cytogenetics, Genetic Mutations and Methylation of CDKN2B and DLC-1 Promoters on Treatment Response to Azacitidine. Ann Hematol. 2020;99(3):527\u201337.","journal-title":"Ann Hematol"},{"key":"15997_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"issue":"15","key":"15997_CR13","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"10","key":"15997_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment ofpatients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"17","key":"15997_CR15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood.2022018604","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ad\u00e8s L, Borate U, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141(17):2047\u201361. https:\/\/doi.org\/10.1182\/blood.2022018604.","journal-title":"Blood"},{"issue":"11","key":"15997_CR16","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1080\/10428194.2020.1775214","volume":"61","author":"A Azizi","year":"2020","unstructured":"Azizi A, Ediriwickrema A, Dutta R, Patel SA, Shomali W, Medeiros B, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020;61(11):2700\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"15997_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Th\u00e9pot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403\u201311.","journal-title":"Blood"},{"key":"15997_CR18","doi-asserted-by":"publisher","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","volume":"104","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555.","journal-title":"Leuk Res"},{"issue":"17","key":"15997_CR19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, P\u00e9rez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312.","journal-title":"Blood"},{"issue":"16","key":"15997_CR20","doi-asserted-by":"publisher","first-page":"22103","DOI":"10.18632\/oncotarget.7899","volume":"7","author":"M Tobiasson","year":"2016","unstructured":"Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M. Ben Azenkoud A Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget. 2016;7(16):22103\u201315.","journal-title":"Oncotarget"},{"issue":"24","key":"15997_CR21","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022;28(24):5272\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"15997_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1186\/s12885-026-16993-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15997-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:07:31Z","timestamp":1790410051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15997-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15997"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15997-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-026-16993-1","URL":"https:\/\/doi.org\/10.1186\/s12885-026-16993-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Institutional Review Boards of Ramathibodi Hospital, Mahidol University (Certificate of approval. No. MURA2023\/754). Consent to participate was not obtained, as the study was conducted retrospectively.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"699"}}